Top 5 Vendors in the Global Bone Cancer Drugs Market 2019-2023 | Technavio
LONDON--(BUSINESS WIRE)-- The emergence of targeted therapies for the treatment of bone cancer is expected to drive market growth. Currently, targeted therapies such as PD-1, PD-L1, and SRC family kinase inhibitors are being approved for the treatment of various types of bone cancers. Companies are also developing therapies which would target the mutated genes and suppress the multiplication of cancer cells in bones. Such factors will encourage patients to prefer bone cancer treatment using targeted therapies. This industry research report also presents a competitive analysis of the market by indication (osteosarcoma, Ewing’s sarcoma, chondrosarcoma, others) and by geography (Asia, Europe, North America, and ROW).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190701005307/en/
Technavio has published a new market research report on the global bone cancer drugs market from 2019-2023. (Graphic: Business Wire)
Competitive vendor landscape
The global bone cancer drugs market is highly competitive with major vendors such as Amgen, Bayer AG, Bristol-Myers Squibb Company, Merck & Co. Inc., and Pfizer Inc. competing based on price, quality, product/service offering, and market presence.
“The rising prevalence of osteosarcoma in younger patients will increase the need for bone cancer drugs and targeted therapies for its treatment. Moreover, the expected approval of novel bone cancer drugs currently in the late stages of their clinical trial will further drive the adoption of bone cancer drugs for osteosarcoma treatment. Thus, such factors are expected to drive the global bone cancer drugs market during the forecast period,” says a senior research analyst at Technavio.
Top five bone cancer drugs market vendors
The company operates in only the Human Therapeutics segment. This segment focuses on the discovery, development, manufacturing, and commercialization of therapeutics for the treatment of various indications. Its offerings include XGEVA, which is a prescription medicine approved for the treatment of metastases bone cancer.
The company runs its operations through four segments, Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Its offerings include VITRAKVI, which is an NTRK inhibitor that is approved for various types of cancers, including bone cancer, caused by a mutation in the NTRK gene.
Bristol-Myers Squibb Company
The company runs its operations through only one segment, BioPharmaceuticals, which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines that help patients prevail over serious diseases. The company’s offerings include OPDIVO, PLATINOL, VePesid, and SPRYCEL.
Merck & Co., Inc.
The company has three segments, Pharmaceutical, Animal Health, and Others. Its offerings include KEYTRUDA, which is a PD-1 inhibitor being studied in Phase II of clinical trials for the treatment of osteosarcoma and various other bone cancers.
The company runs its operations through two segments, Innovative Health, and Essential Health. Its key offerings include Toposar, ADRIAMYCIN, BAVENCIO, and Oncovin, which comes under the Innovative health segment.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Periodontal Therapeutics Market 2019-2023 - The market research study identifies 3M Co., Bausch Health Companies Inc., Den-Mat Holdings LLC, Kaken Pharmaceuticals Co. Ltd., and Teva Pharmaceutical Industries Ltd. as the leading players in the global periodontal therapeutics market.
- Global Non-small Cell Lung Cancer Drugs Market 2019-2023- The market research study identifies AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc.as the leading players in the global non-small cell lung cancer drugs market.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.
Source: Technavio Research